Published in Cleve Clin J Med on January 01, 2006
Phenotypes developed in secretin receptor-null mice indicated a role for secretin in regulating renal water reabsorption. Mol Cell Biol (2007) 1.11
Nephrogenic diabetes insipidus: essential insights into the molecular background and potential therapies for treatment. Endocr Rev (2013) 1.06
Congenital nephrogenic diabetes insipidus: the current state of affairs. Pediatr Nephrol (2012) 1.04
Novel mutations associated with nephrogenic diabetes insipidus. A clinical-genetic study. Eur J Pediatr (2015) 0.80
Neurosarcoidosis-associated central diabetes insipidus masked by adrenal insufficiency. BMJ Case Rep (2015) 0.79
Diabetes insipidus contributes to traumatic brain injury pathology via CD36 neuroinflammation. Med Hypotheses (2013) 0.79
3T renal (23)Na-MRI: effects of desmopressin in patients with central diabetes insipidus. MAGMA (2013) 0.79
Deficiency of antidiuretic hormone: a rare cause of massive polyuria after kidney transplantation. Korean J Pediatr (2016) 0.75
Diabetes insipidus: The other diabetes. Indian J Endocrinol Metab (2016) 0.75
Diabetes insipidus uncovered during conservative management of complicated acute appendicitis. Clin Case Rep (2016) 0.75
Pediatric anterior visual pathway gliomas: trends in fluid and electrolyte dynamics and their management nuances. Childs Nerv Syst (2014) 0.75
Metformin: an update. Ann Intern Med (2002) 5.62
Sleep duration among black and white Americans: results of the National Health Interview Survey. J Natl Med Assoc (2008) 3.82
Awareness of kidney disease and relationship to end-stage renal disease and mortality. Am J Med (2012) 2.24
Prevalence of CKD and comorbid illness in elderly patients in the United States: results from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis (2010) 2.18
CKD in the United States: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004. Am J Kidney Dis (2008) 1.71
Adverse effects of phytoestrogens on reproductive health: a report of three cases. Complement Ther Clin Pract (2008) 1.62
The case for low carbohydrate diets in diabetes management. Nutr Metab (Lond) (2005) 1.61
Diabetes mellitus and CKD awareness: the Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES). Am J Kidney Dis (2009) 1.52
Dietary carbohydrate restriction in type 2 diabetes mellitus and metabolic syndrome: time for a critical appraisal. Nutr Metab (Lond) (2008) 1.44
Obstructive sleep apnea and cardiovascular disease: role of the metabolic syndrome and its components. J Clin Sleep Med (2008) 1.38
CKD and cardiovascular disease in screened high-risk volunteer and general populations: the Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004. Am J Kidney Dis (2008) 1.37
Abrogation of oxidative stress improves insulin sensitivity in the Ren-2 rat model of tissue angiotensin II overexpression. Am J Physiol Endocrinol Metab (2004) 1.33
Association of diabetes and hepatitis C infection: epidemiologic evidence and pathophysiologic insights. Curr Diab Rep (2004) 1.22
Hypertension and obesity. Recent Prog Horm Res (2004) 1.20
The relationship between hyperinsulinemia, hypertension and progressive renal disease. J Am Soc Nephrol (2004) 1.16
Sleep duration and the risk of diabetes mellitus: epidemiologic evidence and pathophysiologic insights. Curr Diab Rep (2010) 1.14
Diabetes mellitus in CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition and Examination Survey (NHANES) 1999-2004. Am J Kidney Dis (2008) 1.12
Oxidative stress, glucose metabolism, and the prevention of type 2 diabetes: pathophysiological insights. Antioxid Redox Signal (2007) 1.12
Heart disease in diabetic patients. Curr Diab Rep (2003) 1.09
Antiepileptic drugs and bone metabolism. Nutr Metab (Lond) (2006) 1.01
Obesity is associated with increased parathyroid hormone levels independent of glomerular filtration rate in chronic kidney disease. Metabolism (2009) 1.00
Cardiovascular disease risk reduction with sleep apnea treatment. Expert Rev Cardiovasc Ther (2010) 0.99
Cardiometabolic syndrome: pathophysiology and treatment. Curr Hypertens Rep (2003) 0.98
Linking sleep duration and obesity among black and white US adults. Clin Pract (Lond) (2013) 0.96
Dysglycemia predicts cardiovascular and kidney disease in the Kidney Early Evaluation Program. J Clin Hypertens (Greenwich) (2010) 0.94
Obesity, Diabetes, the Cardiorenal Syndrome, and Risk for Cancer. Cardiorenal Med (2012) 0.94
Gender disparity in outcomes of care and management for diabetes and the metabolic syndrome. Curr Diab Rep (2006) 0.93
The emerging role of biomarkers in diabetic and hypertensive chronic kidney disease. Curr Diab Rep (2010) 0.93
Diabetic Cardiovascular Disease Predicts Chronic Kidney Disease Awareness in the Kidney Early Evaluation Program. Cardiorenal Med (2011) 0.93
Sleep apnea and diabetes: insights into the emerging epidemic. Curr Diab Rep (2011) 0.92
Update on the prevention of type 2 diabetes. Curr Diab Rep (2011) 0.92
Group visits in the management of diabetes and hypertension: effect on glycemic and blood pressure control. Curr Diab Rep (2009) 0.92
Differential effect of obesity on bone mineral density in White, Hispanic and African American women: a cross sectional study. Nutr Metab (Lond) (2005) 0.92
Hypertension in pregnancy. Curr Hypertens Rep (2005) 0.92
Diabetes, hypertension, and cardiovascular derangements: pathophysiology and management. Curr Hypertens Rep (2004) 0.90
Antihypertensive medications and their effects on lipid metabolism. Curr Diab Rep (2008) 0.88
Sudden cardiac death in patients with diabetes. Curr Diab Rep (2004) 0.88
Effect of ethnicity on the progression of diabetic kidney disease independent of glycemic control. Am J Nephrol (2009) 0.85
Heart failure in diabetic patients: utility of beta-blockade. J Card Fail (2003) 0.85
The Association between Parathyroid Hormone Levels and the Cardiorenal Metabolic Syndrome in Non-Diabetic Chronic Kidney Disease. Cardiorenal Med (2011) 0.85
New-onset diabetes after hemodialysis initiation: impact on survival. Am J Nephrol (2010) 0.85
The association of parathyroid hormone with ESRD and pre-ESRD mortality in the Kidney Early Evaluation Program. J Clin Endocrinol Metab (2012) 0.84
Pleiotropic effects of inhibitors of the RAAS in the diabetic population: above and beyond blood pressure lowering. Curr Diab Rep (2010) 0.84
Treatment of hypertension in metabolic syndrome: implications of recent clinical trials. Curr Diab Rep (2009) 0.83
Hypertension in patients with Cushing's disease: pathophysiology, diagnosis, and management. Curr Hypertens Rep (2005) 0.83
Telephone-delivered behavioral intervention among blacks with sleep apnea and metabolic syndrome: study protocol for a randomized controlled trial. Trials (2014) 0.83
Review on "Atkins Diabetes Revolution: The Groundbreaking Approach to Preventing and Controlling Type 2 Diabetes" by Mary C. Vernon and Jacqueline A. Eberstein. Nutr Metab (Lond) (2004) 0.82
Hypertension in people with diabetes and the metabolic syndrome: pathophysiologic insights and therapeutic update. Curr Diab Rep (2007) 0.82
High-dose atorvastatin after stroke or transient ischemic attack: The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. J Cardiometab Syndr (2008) 0.81
Cardiometabolic syndrome and chronic kidney disease. Curr Diab Rep (2006) 0.81
Resistant hypertension and sleep apnea: pathophysiologic insights and strategic management. Curr Diab Rep (2011) 0.80
Antihypertensive agents, insulin sensitivity, and new-onset diabetes. Curr Diab Rep (2007) 0.79
Prevention of type 2 DM: implications for adolescents and young adults. Pediatr Endocrinol Rev (2008) 0.78
Cardiovascular risk reduction via increasing HDL cholesterol: the promise of the dal-OUTCOMES Trial. Curr Diab Rep (2011) 0.78
High Prevalence of Hypertension and Other Cardiometabolic Risk Factors in US- and Caribbean-Born Blacks with Chest Pain Syndromes. Cardiorenal Med (2012) 0.77
Prevention of type 2 diabetes: an update. Curr Diab Rep (2007) 0.77
Uncovering glucose abnormalities in people with hepatitis C infection: should oral glucose tolerance test become a standard of care? Am J Gastroenterol (2008) 0.76
Admission hyperglycemia and length of hospital stay in patients with diabetes and heart failure: a prospective cohort study. Congest Heart Fail (2008) 0.76
Telmisartan and cardioprotection. Vasc Health Risk Manag (2011) 0.76
Challenges in the diagnosis and management of new-onset diabetes after transplantation. Curr Diab Rep (2005) 0.76
Narrowed Aortoseptal Angle Is Related to Increased Central Blood Pressure and Aortic Pressure Wave Reflection. Cardiorenal Med (2012) 0.76
Hypertension management in the high cardiovascular risk population. Int J Hypertens (2013) 0.75
Hypertension after renal transplant. J Clin Hypertens (Greenwich) (2007) 0.75
Calcium channel blockers reduce risk of stroke in people with hypertension. Commentary. Evid Based Cardiovasc Med (2005) 0.75
ONTARGET: use of ramipril, telmisartan, or both in patients with high cardiovascular risks. Curr Diab Rep (2009) 0.75
What are the long-term cardiovascular effects of treatment with rosiglitazone? Curr Diab Rep (2008) 0.75
Statins and CVD prevention in the diabetic population: implications of the CARDS trial. Curr Diab Rep (2005) 0.75
When the heart and the mind collide: cardiovascular risk factors and antipsychotic use in the schizophrenic population. J Cardiometab Syndr (2009) 0.75
Hepatitis C and the risk of cardiovascular disease: an evolving epidemic? Expert Rev Cardiovasc Ther (2006) 0.75
Heart failure: metabolic derangements and therapeutic rationale. Expert Rev Cardiovasc Ther (2007) 0.75
The Diabetes Prevention Program. Curr Diab Rep (2003) 0.75
Mitigating the cardiovascular risk of anemia in patients with type 2 diabetes and CKD: Does darbepoetin help? The TREAT Trial. Curr Diab Rep (2010) 0.75
Stroke prevention in diabetic and other high cardiovascular risk patients. Curr Diab Rep (2005) 0.75
The DREAM trial and the prospect of diabetes prevention. Curr Diab Rep (2006) 0.75
Clinical trials report. Hypertensive diabetic patients: INVESTing in the prevention of cardiovascular disease. Curr Hypertens Rep (2005) 0.75
Therapeutic interventions for hypertension in metabolic syndrome: a comprehensive approach. Expert Rev Cardiovasc Ther (2007) 0.75
Gender disparities in the control of cardiovascular risk factors in people with diabetes. J Clin Hypertens (Greenwich) (2005) 0.75
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack (ALLHAT) Trial: focus on the diabetic patient. Curr Hypertens Rep (2004) 0.75
Bone mineral density in African–American women with symptomatic uterine leiomyoma. Womens Health (Lond Engl) (2010) 0.75
Challenges in the diagnosis and management of renal artery stenosis. Curr Hypertens Rep (2005) 0.75
Cardiovascular disease in diabetes and the cardiometabolic syndrome: focus on minority women. Curr Diab Rep (2005) 0.75
Posttransplant diabetes and hypertension: pathophysiologic insights and therapeutic rationale. Curr Diab Rep (2008) 0.75